Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial

References

• Bandello F, Battaglia Parodi M, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol. 2010;47:73–110.
   PubMedGoogle Scholar
• Williams R, Airey M, Baxter H, Forrester J, tKennedy-Marin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond). 2004;18(10):963–983. doi:10.1038/sj.eye.6701476
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–1394. doi:10.1016/j.ophtha.2015.03.024
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63(3):20–68. doi:10.1016/j.preteyeres.2017.10.006
   Web of Science ®Google Scholar
• Urias EA, Urias GA, Monickaraj F, McGuire P, Das A. Novel therapeutic targets in diabetic macular edema: beyond VEGF. Vision Research. 2017;139:221–227. doi:10.1016/j.visres.2017.06.015
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang N, Schachat AP, Bao S, Gillies MC. Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med. 2014;14:376–384.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Diabetic retinopathy clinical research network. randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077. doi:10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE research group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. doi:10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi:10.1016/j.ophtha.2014.05.006
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study). Diabetes Care. 2010;33:2399–2405. doi:10.2337/dc10-0493
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–2151. doi:10.1016/j.ophtha.2010.08.016
   PubMed Web of Science ®Google Scholar
• Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686–694. doi:10.1016/j.ajo.2011.03.033
   PubMed Web of Science ®Google Scholar
• Vujosevic S, Torresin T, Bini S, et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol. 2017;95:464–471. doi:10.1111/aos.13294
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Diabetic retinopathy clinical research network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–614. doi:10.1016/j.ophtha.2010.12.033
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother. 2014;15:953–959. doi:10.1517/14656566.2014.896899
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Bellfort R Jr, et al. Ozurdex MEAD study group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol. 2013;7:1423–1428. doi:10.2147/OPTH.S48364
   PubMedGoogle Scholar
• Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina. 2014;34(4):719–724. doi:10.1097/IAE.0b013e3182a48958
   PubMed Web of Science ®Google Scholar
• Cicinelli MV, Cavalleri M, Querques L, Rabiolo A, Bandello F, Querques G. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular edema. Br J Ophthalmol. 2017;101:1689–1693. doi:10.1136/bjophthalmol-2017-310242
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Ozurdex champlain study group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–923. doi:10.1097/IAE.0b013e318206d18c
   PubMed Web of Science ®Google Scholar
• Bucolo C, Gozzo L, Longo L, Mansueto S, Vitale DC, Drago F. Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies. Journal of Pharmacological Sciences. 2018;138:219–232. doi:10.1016/j.jphs.2018.11.001
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of corticosteroids for DME. Invest Ophthalmol Vis Sci. 2018;59:1–12. doi:10.1167/iovs.17-22259
   PubMed Web of Science ®Google Scholar
• Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129(7):914–920. doi:10.1001/archophthalmol.2011.39
   PubMedGoogle Scholar
• Maturi RK, Glassman AR, Liu D, et al. Diabetic retinopathy clinical research network. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi:10.1001/jamaophthalmol.2017.4914
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Busch C, Mali O, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24 month cohort study the “DR- pro DEX study”. Acta Diabetologica. 2018;55:541–547. doi:10.1007/s00592-018-1117-z
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long term effects of intravireal 0,19 mg fluocinolone acetonide implanto n progression and regression of diabetic retinopathy. Ophthalmology. 2017;124:440–449. doi:10.1016/j.ophtha.2016.11.034
   PubMed Web of Science ®Google Scholar
• Chang-lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained release dexamethasone intravitreal implant. IOVS. 2011;52(1):80–86.
   PubMed Web of Science ®Google Scholar
• Escobar-Barranco JJ, Pina-Marín B, Fernandez-Bonet M. Dexamethasone implants in patients with naïve or or refractory diffuse diabetic macular edema. Opthalmologica. 2015;233:176–185. doi:10.1159/000371770
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116(5):902–911. doi:10.1016/j.ophtha.2009.02.002
   PubMed Web of Science ®Google Scholar
• Elman MJ, Raden RZ, Sloan MD, et al. Diabetic retinopathy clinical research network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–1449. doi:10.1016/j.ophtha.2008.06.015
   Web of Science ®Google Scholar
• Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and phamacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110(2):259–266. doi:10.1001/archopht.1992.01080140115038
   PubMed Web of Science ®Google Scholar